Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Titel:
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Auteur:
Stein, Anthony Franklin, Janet L. Chia, Victoria M. Arrindell, Deborah Kormany, William Wright, Jacqueline Parson, Mandy Amouzadeh, Hamid R. Choudhry, Jessica Joseph, Guiandre